Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Passage Bio, Inc. (PASG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5500-0.2100 (-7.61%)
At close: 04:00PM EDT
2.3400 -0.21 (-8.24%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.7600
Open2.8400
Bid2.1100 x 3200
Ask2.5500 x 1000
Day's Range2.4750 - 2.8400
52 Week Range1.5700 - 16.1400
Volume3,991,154
Avg. Volume552,351
Market Cap138.485M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-3.5050
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PASG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Passage Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

    PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference being held from June 13-16, 2022 in Rancho Palos Verdes, CA. Format: Fireside Chat Date: Thursday, June 16, 2

  • GlobeNewswire

    Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

    • PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for

  • American City Business Journals

    Passage Bio and CEO Bruce Goldsmith part ways

    The company named an interim CEO and an interim executive chairman while it conducts a search for a new chief executive.

Advertisement
Advertisement